【摘要】 目的 探讨胰高血糖素样肽-1受体激动剂司美格鲁肽对2型糖尿病患者MoCA认知评分及血清β-淀粉样蛋白1-42(Aβ1-42)水平的影响，旨在为改善2型糖尿病患者的认知功能提供新的治疗途径。方法 选取2022年12月—2023年12月在亳州市人民医院内分泌科收治住院的60例2型糖尿病患者作为研究对象，采用随机数字法分为2组，每组30例。常规组予以口服药物或(和)胰岛素降糖治疗，司美格鲁肽组予以司美格鲁肽联合口服药物或(和)胰岛素治疗，周期为6个月。比较治疗后2组MoCA认知功能评分及血清Aβ1-42水平。结果 治疗后2组空腹血糖(FBG)、糖化血红蛋白比值(HbA1c%)、甘油三酯(TG)、总胆固醇(TC)、胰岛素抵抗指数(HOMA-IR)比较，差异均无统计学意义(P>0.05)。司美格鲁肽组MoCA认知评分[28.00(26.00,29.00)分]高于常规组[24.50(23.00,26.00)分，P<0.001],血清Aβ1-42水平[(100.67±23.34)pg/mL]低于常规组[(119.03±34.43)pg/mL,P<0.001]。结论 司美格鲁肽可降低2型糖尿病患者血清Aβ1-42水平，升高MoCA认知评分，改善认知功能。更多还原

【Abstract】 Objective This study explores the effects of the glucagon-like peptide-1 receptor agonist semaglutide on the MoCA cognitive score and serum β-amyloid protein 1-42(Aβ1-42) levels in patients with type 2 diabetes, aiming to provide a new therapeutic approach for improving the cognitive function of patients with type 2 diabetes. Methods Sixty patients with type 2 diabetes mellitus admitted to the Endocrinology Department of Bozhou People’s Hospital from December 2022 to December 2023 were selected as the research subjects and randomly divided into two groups by random number method, with 30 cases in each group. The conventional group was treated with oral hypoglycemic drugs and/or insulin, while the semaglutide group was treated with semaglutide combined with oral hypoglycemic drugs and/or insulin. The treatment period was 6 months. The MoCA cognitive function scores and serum Aβ1-42 levels of the two groups after treatment were compared. Results There were no statistically significant differences in fasting blood glucose(FBG), glycosylated hemoglobin ratio(HbA1c%), triglycerides(TG), total cholesterol(TC), and insulin resistance index(HOMA-IR) between the two groups after treatment(P>0.05). The MoCA cognitive score of the semaglutide group [28.00(26.00, 29.00) points] was higher than that of the control group [24.50(23.00, 26.00) points, P<0.001], and the serum Aβ1-42 level [(100.67±23.34) pg/mL] was lower than that of the control group [(119.03±34.43) pg/mL, P<0.001]. Conclusion Semaglutide can reduce the serum Aβ1-42 level in patients with type 2 diabetes, increase the MoCA cognitive score, and improve cognitive function.更多还原